<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bossuyt,X.</style></author><author><style face="normal" font="default" size="100%">Humbel,R.</style></author><author><style face="normal" font="default" size="100%">Mewis,A.</style></author><author><style face="normal" font="default" size="100%">Servais,G.</style></author><author><style face="normal" font="default" size="100%">Tomasi,J.P.</style></author><author><style face="normal" font="default" size="100%">C . Van Campenhout</style></author><author><style face="normal" font="default" size="100%">L. Van Hoovels</style></author><author><style face="normal" font="default" size="100%">Vercammen,M.</style></author><author><style face="normal" font="default" size="100%">Damoiseaux,J.</style></author><author><style face="normal" font="default" size="100%">Wim Coucke</style></author><author><style face="normal" font="default" size="100%">P Van de Walle</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Belgian recommendations on ANA, anti-dsDNA and anti-ENA antibody testing704</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Clin.Belg.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">2010</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">ALL</style></keyword><keyword><style  face="normal" font="default" size="100%">ANA</style></keyword><keyword><style  face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Antinuclear</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibody</style></keyword><keyword><style  face="normal" font="default" size="100%">Antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">Antinuclear antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">assessment</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoantibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoimmune Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgian</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Dna</style></keyword><keyword><style  face="normal" font="default" size="100%">European</style></keyword><keyword><style  face="normal" font="default" size="100%">external</style></keyword><keyword><style  face="normal" font="default" size="100%">External quality assessment</style></keyword><keyword><style  face="normal" font="default" size="100%">External quality assessment scheme</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluorescent Antibody Technique,Indirect</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">INFORMATION</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Laboratories</style></keyword><keyword><style  face="normal" font="default" size="100%">Marker</style></keyword><keyword><style  face="normal" font="default" size="100%">Markers</style></keyword><keyword><style  face="normal" font="default" size="100%">national</style></keyword><keyword><style  face="normal" font="default" size="100%">Nuclear</style></keyword><keyword><style  face="normal" font="default" size="100%">ON</style></keyword><keyword><style  face="normal" font="default" size="100%">outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Paper</style></keyword><keyword><style  face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">present</style></keyword><keyword><style  face="normal" font="default" size="100%">Print</style></keyword><keyword><style  face="normal" font="default" size="100%">Quality</style></keyword><keyword><style  face="normal" font="default" size="100%">Questionnaire</style></keyword><keyword><style  face="normal" font="default" size="100%">Questionnaires</style></keyword><keyword><style  face="normal" font="default" size="100%">recommendation</style></keyword><keyword><style  face="normal" font="default" size="100%">Recommendations</style></keyword><keyword><style  face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">STANDARDIZATION</style></keyword><keyword><style  face="normal" font="default" size="100%">standards</style></keyword><keyword><style  face="normal" font="default" size="100%">statistics &amp; numerical data</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">TESTING</style></keyword><keyword><style  face="normal" font="default" size="100%">varieties</style></keyword><keyword><style  face="normal" font="default" size="100%">variety</style></keyword><keyword><style  face="normal" font="default" size="100%">work</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1/4/2014</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">86</style></number><volume><style face="normal" font="default" size="100%">69</style></volume><pages><style face="normal" font="default" size="100%">83 - 86</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Autoantibodies to nuclear antigens, i.e. antinuclear antibodies (ANA), antibodies to double-stranded DNA (dsDNA) and extractable nuclear antigens (ENA), are useful as diagnostic markers for a variety of autoimmune diseases. In March 2010, the Belgian national External Quality Assessment Scheme sent a questionnaire on ANA, anti-dsDNA and anti-ENA antibody testing designed by the Dutch EASI (European Autoimmunity Standardization Initiative) team, to all clinical laboratories performing ANA testing. Virtually all laboratories completed the questionnaire (97.7%, 127/130). This paper discusses the results of this questionnaire and provides valuable information on the state-of-the-art of ANA, anti-dsDNA and anti-ENA antibody testing as practiced in the Belgian laboratories. In addition, this work presents practical recommendations developed by the members of the advisory board of the scheme as a result of the outcome of this study</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">704</style></custom1><section><style face="normal" font="default" size="100%">83</style></section></record></records></xml>